Send a text

Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focusing solely on HIPAA leaves a massive, unregulated gap in your compliance strategy. We break down the "layered system" of risk—from aggressive state privacy laws and medical privacy statutes to the DOJ’s massive 2025 Bulk Data Rule. Whether you’re running patient engagement campaigns or leveraging marketing automation, you’ll learn why the tools you use to scale might be the very tools that trigger a regulatory audit. Don't leave your firm's reputation to a "narrow slice" of engagement.

Support the show

www.kulkarnilawfirm.com

Send a text

The "handshake" era of cosmetic compliance is officially over. Under new authorities in Sections 605, 610, and 704, the FDA has moved from simple observation to an aggressive "access and copy" mandate. In this episode, Darshan Kulkarni breaks down the "SAHCOD" threat and explains why your internal communications, medical assessments, and even cross-contamination logs are now fair game for federal investigators. If you handle raw materials or shared manufacturing equipment, your entire catalog could be at risk of a forensic audit. Learn where the FDA's power ends—and where your defense begins.

Support the show

www.kulkarnilawfirm.com

Send a text

In clinical research, if it isn't documented, it never happened. Many site owners mistake a competent team for a compliant one—a mistake that leads to disastrous FDA inspections and lost sponsor contracts. In this KLF Deep Dive, Darshan Kulkarni reveals the specific training SOPs, log templates, and contract clauses required to protect your site. Learn how to bridge the gap between "doing the work" and "proving the work" so you can demonstrate a culture of readiness that sponsors trust.

Support the show

www.kulkarnilawfirm.com

Send a text

Is your marketing team building a brand or a federal case?
In this episode, we deconstruct the $1.2 billion collapse of Boom Care. What looked like a runaway success story in the wound care space was actually a systematic violation of the False Claims Act. We break down the three fatal mistakes that led to 15-year prison sentences for executives: prioritizing reimbursement over medical necessity, incentivizing volume over value, and treating compliance as an afterthought. If you are an executive in biopharma or med-tech, this is a mandatory masterclass in where "aggressive growth" ends and criminal exposure begins.

Support the show

www.kulkarnilawfirm.com

Send a text

In January 2026, the FDA sharpened the line between helpful software and regulated medical devices. If your AI sits inside an EHR, providing "black box" recommendations that a clinician can’t independently verify in seconds, you aren't just drifting into a regulatory gray area, you’re likely standing outside the "safe zone."

In this episode, we break down the high-stakes intersection of FDA transparency, OIG inducement analysis, and the reality of clinical workflows.

In this episode, we cover:

• The 2026 FDA Update: Why "independence" is the new metric for non-device CDS.
• The Transparency Test: If a physician has to call your engineering team to explain a recommendation, you've already lost.
• OIG & The Anti-Kickback Statute: How "nudging" prescribing behavior creates massive financial liability, regardless of what you call your software.
• Automation Bias: How "fast and confident" AI leads to clinician reliance that regulators now view as a red flag.
• The FTC Factor: Why vague disclosures and hidden logic are no longer defensible under consumer protection standards.

Key Takeaway:

Regulators don't care if the tech works; they care if the compliance story holds up. If you cannot prove your recommendations are separated from commercial influence and fully explainable, you are exposed.

Are you ready to defend your AI? Don't wait for an investigator to walk through your door.

Subscribe to the KLF Deep Dive Podcast & Newsletter to navigate these risks before they turn into enforcement problems.

Support the show

www.kulkarnilawfirm.com

Send a text

In this episode, Darshan Kulkarni exposes a massive legal shift that is quietly dismantling the "Practice of Medicine" defense. We track the whiplash from the 2021 Ivermectin court victories to the DOJ’s aggressive 2025 memorandum targeting gender-affirming care.

Is "Intended Use" being weaponized as a high-tech surveillance tool? If the government can criminalize the intent behind a legal hormone, what does that mean for every manufacturer and physician operating in the off-label space? Darshan breaks down the April 2025 DOJ Memo and why your compliance strategy is likely outdated. This isn't just a policy change; it’s a precedent that puts every drug in the market at risk.

Support the show

www.kulkarnilawfirm.com

Send a text

In this episode of the KLF Deep Dive, Darshan Kulkarni sits down with Phyllis Marcus, Vice President of the National Advertising Division (NAD) and former FTC veteran. They unpack the complex "grey area" where healthcare professional (HCP) communications bleed into the public consumer space. Phyllis reveals why labeling an ad "For Healthcare Professionals Only" may no longer protect a company from regulatory scrutiny and explains the NAD’s role as an independent adjudicator in high-stakes pharmaceutical disputes. If you are navigating the intersection of FDA, FTC, and NAD jurisdictions, this masterclass in advertising law is essential listening.

Support the show

www.kulkarnilawfirm.com

Send a text

State governments are racing to innovate by allowing AI to renew and improve prescriptions—but are they walking into a federal trap? In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the "Utah Sandbox" model and the three massive warning signs flashing for the life sciences industry. From misdiagnosis risks to the nightmare of liability ownership, we explore why "innovation" doesn't grant immunity from federal law or malpractice lawsuits. If you are a healthcare executive or legal professional, this is the regulatory reality check you can't afford to miss.

Support the show

www.kulkarnilawfirm.com